1 / 9

3 D (Paritaprevir -Ritonavir -Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-II

Phase 3. Treatment Experienced. 3 D (Paritaprevir -Ritonavir -Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-II. Zeuzem S, et al. N Engl J Med. 2014;370:1604-14. 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1 SAPPHIRE -II: Study Design.

mathilde-martinez
Télécharger la présentation

3 D (Paritaprevir -Ritonavir -Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 TreatmentExperienced 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1SAPPHIRE-II Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  2. 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II: Study Design Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  3. 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II: Regimens 0 12 24 36 Week Double blind 3D + Ribavirin Active N = 297 SVR12 Open label (data pending) Placebo 3D + Ribavirin PlaceboN = 97 SVR12 3D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Drug Dosing3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily)+ Dasabuvir: 250 mg twice dailyRibavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  4. 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II Study: Baseline Characteristics Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  5. 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II: Results SAPPHIRE-II: Results by Genotype 1 Subtype 286/297 166/173 119/123 Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  6. 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II: Results SAPPHIRE-II: Results by Prior Treatment Response 286/297 82/86 65/65 139/146 Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  7. 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II Study: Key Adverse Events Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  8. 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II: Conclusions Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.

  9. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related